Lung Cancer Alliance: April 2017

Lung Cancer Alliance: April 2017

Founded: 
1995
Location: 
Washington, D.C.
Mission: 
Saving lives, advancing research and changing health policy by empowering those living with and at risk for lung cancer.

Lung Cancer Alliance (LCA) is the leading and highest rated nonprofit organization dedicated to fighting lung cancer in the nation. Since 1995, we have played a critical role in every major advance – changing how we support, talk about, detect and treat the disease – and turning those impacted into survivors. Using a science-based, strategic approach, our vision is to triple the number of survivors over the next decade. Reaching this goal requires a collaborative effort that links transformative early detection and treatment research, patient and provider services, and changes to health policies that increase research funding and ensure access to high quality and affordable care.

Since moving to Washington, D.C., over a decade ago, Lung Cancer Alliance’s (LCA) core focus has been to improve outcomes for people diagnosed with lung cancer.  Our goals are three-fold: (1) provide personalized support services to address our communities’ unique needs; (2) increase and advance research that fills in gaps and accelerates breakthroughs; (3) devise more coordinated, comprehensive federal plans of action that ensure access to high quality and affordable care.

With over 220,000 Americans diagnosed with lung cancer each year and close to 160,000 dying from the disease annually as well as a long held stigma that has contributed to a stagnation in survival rates and federal research funding, it is easy to understand why LCA’s health policy work has played such a groundbreaking role.    

Lung Cancer Alliance has seen advocacy gains on several fronts to help move the needle in the fight against lung cancer including working to establish the first-ever dedicated federal research funding pipeline for the disease in 2008 through the Congressionally Directed Medical Research Programs (CDMRP) totaling over $120 million to date, enacting legislation that requires NCI to give increased priority to lung cancer research strategies and spearheading the 10-year long effort to secure lung cancer screening as a fully covered preventive service for the millions at high risk for the disease.

“In order to improve survivorship for those impacted by this terrible disease, increased federal funding is crucial for early detection and treatment research to improve our health care delivery system,” said Laurie Fenton Ambrose, President & CEO of LCA. “Life-saving work needs strength in numbers and Research!America gives us valuable support to advance this effort.”

Lung Cancer Alliance will remain the leading advocacy voice for early detection and treatment research at both the regulatory and legislative level to further provide care and support for patients and those at risk. Whether working with Congress through the Congressional Lung Cancer Caucus or participating in further innovative research initiatives, LCA aims to continue elevating the voice of the lung cancer community by devising policy strategies that sustain federal research funding, support accelerated drug approval processes and more personalized research strategies, prevent barriers to access to high-quality and affordable care and enable collaboration on research endeavors to change the status quo by bringing the most promising treatments to patients sooner. And, lastly, Lung Cancer Alliance will further efforts, begun over 5 years ago, to expand the responsible implementation of lung cancer screening best practices in communities across the country. 

“Research!America’s work helps ‘put gas in our tank’ as it lays the foundation for collaborations with other stakeholder groups who value increased funding for research efforts that impact public health,” said Fenton Ambrose. “Their partnership provides avenues to amplify our collective voices to truly make a difference on issues that matter to all of us.”  

Media Contacts

Suzanne Ffolkes
VP Communications
571-482-2710

Anna Briseño
Senior Manager of Communications
571-482-2737

The capabilities are enormous, a little bit of research can pay off quite a bit in the long run.
Paul D’ Addario, retinitis pigmentosa patient